Prostate Cell News Volume 8.11 | Mar 24 2017

TOP STORY

Effective Combinatorial Immunotherapy for Castration-Resistant Prostate Cancer

The authors developed a novel chimeric mouse model of metastatic castration-resistant prostate cancer to efficiently test combination therapies in an autochthonous setting. [Nature] Abstract

(Ranked by impact factor of the journal)

LABORATORY RESEARCH

A Single-Copy Sleeping Beauty Transposon Mutagenesis Screen Identifies New PTEN-Cooperating Tumor Suppressor Genes

Scientists analyzed 278 transposition-induced prostate, breast and skin tumors detected tissue-specific and shared data sets of known and candidate genes involved in cancer. They validated ZBTB20, CELF2, PARD3, AKAP13 and WAC, which were identified by their screens in multiple cancer types, as new tumor suppressor genes in prostate cancer. [Nat Genet] Abstract | Press Release

Development of Peptidomimetic Inhibitors of the ERG Gene Fusion Product in Prostate Cancer

Researchers identified a series of peptides that interact specifically with the DNA binding domain of ERG. ERG inhibitory peptides (EIPs) and derived peptidomimetics bound ERG with high affinity and specificity, which lead to proteolytic degradation of the ERG protein. The EIPs attenuated ERG-mediated transcription, chromatin recruitment, protein-protein interactions, cell invasion and proliferation, and tumor growth. [Cancer Cell] Abstract | Press Release

The Drebrin/EB3 Pathway Drives Invasive Activity in Prostate Cancer

Investigators showed that the drebrin/EB3 pathway, which co-ordinates dynamic microtubule/actin filament interactions underlying cell shape changes in response to guidance cues, plays a role in prostate cancer cell invasion. [Oncogene] Full Article

FOXA1 Inhibits Prostate Cancer Neuroendocrine Differentiation

Scientists demonstrated that FOXA1 loss drives neuroendocrine (NE) differentiation, demarcated by phenotypical changes and NE prostate cancer marker expressions. [Oncogene] Abstract

1,4-Substituted Triazoles as Nonsteroidal Anti-Androgens for Prostate Cancer Treatment

Researchers report the preparation of a small library of novel 1,4-substituted triazoles with androgen receptor (AR) antagonistic activity. Biological and theoretical evaluation demonstrated that the introduction of the triazole core in the scaffold of nonsteroidal antiandrogens allowed the development of small molecules with improved overall AR-antagonist activity. [J Med Chem] Abstract | Graphical Abstract

Multinucleated Polyploidy Drives Resistance to Docetaxel Chemotherapy in Prostate Cancer

The authors investigated role of multinucleated polyploid cells in clinical relapse of castration-resistant prostate cancer. Docetaxel-induced polyploid cells undergo mitotic slippage and eventually spawn mononucleated cells via asymmetric cell division or neosis. [Br J Cancer] Abstract

The Role of CREB3L4 in the Proliferation of Prostate Cancer Cells

Scientists investigated the role of the metabolism-associated protein, CREB3L4, in the proliferation of prostate cancer cells. They also demonstrated that CREB3L4 directly interacts with the AR, and increases the binding of AR to androgen response elements. [Sci Rep] Full Article

CLINICAL RESEARCH

Randomized Trial of a Hypofractionated Radiation Regimen for the Treatment of Localized Prostate Cancer

The authors hypothesized that hypofractionation versus conventional fractionation is similar in efficacy without increased toxicity. They conducted a multicenter randomized noninferiority trial in intermediate-risk prostate cancer. The five-year biochemical-clinical failure disease-free survival was 85% in both arms. [J Clin Oncol] Full Article | Press Release | Video

Clinical Outcomes from Androgen Signaling–Directed Therapy after Treatment with Abiraterone Acetate and Prednisone in Patients with Metastatic Castration-Resistant Prostate Cancer: Post Hoc Analysis of COU-AA-302

Scientists investigated clinical outcomes associated with subsequent abiraterone acetate plus prednisone and enzalutamide in a post hoc analysis of COU-AA-302. Prostate-specific antigen (PSA) response was assessed. The PSA response rate was 44% and 67%, respectively. [Eur Urol] Full Article

A Pilot Trial Evaluating Zoledronic Acid Induced Changes in [¹⁸F]FMAU-Positron Emission Tomography Imaging of Bone Metastases in Prostate Cancer

Researchers conducted a pilot trial utilizing 1-(2′-deoxy-2′-[18F]fluoro-β-d-arabinofuranosyl)thymine ([¹⁸F]FMAU) as a tumor tracer in positron emission tomography and evaluated its reproducibility, and changes in maximum and peak standardized uptake value with zoledronic acid treatment in castrate resistant prostate cancer patients with bone metastases. [Mol Imaging Biol] Abstract

Low-Risk Prostate Cancer: Identification, Management, and Outcomes

The incidence of low-risk prostate cancer (PCa) has increased as a consequence of prostate-specific antigen testing. The authors examine recent literature regarding low-risk PCa and the available prognostic and therapeutic options. [Eur Urol] Full Article

Visit our reviews page to see a complete list of reviews in the prostate cell research field.

Studies Featuring GenomeDx’s Bladder Cancer Research and Decipher Post-Op Selected for Awards

GenomeDx Biosciences announced that six abstracts featuring Decipher Genomics Resource Information Database and Decipher^® Prostate Cancer Classifier tests will be presented. [Press release from GenomeDx Biosciences discussing research to be presented at the 32^nd Annual European Association of Urology (EAU) Congress, London] Press Release

Topsalysin Data from Successful Phase IIa Localized Prostate Cancer Study to Be Presented

Sophiris Bio Inc. announced that data from its successful Phase IIa study of topsalysin, which evaluated the drug as a focal treatment for localized prostate cancer, will be presented as a poster. [Press release from Sophiris Bio Inc. discussing research to be presented at the 32^nd Annual European Association of Urology (EAU) Congress, London] Press Release

Exact Imaging Introduces New FusionVu™ Micro-US/MRI Fusion to Complement its ExactVu™ Micro-Ultrasound System for Prostate Imaging and Biopsy

Exact Imaging introduced its new FusionVu™ micro-US/MRI fusion application to complement its ExactVu™ micro-ultrasound system for prostate imaging and biopsy. FusionVu will be demonstrated at the European Association of Urology (EAU). [Press release from Exact Imaging discussing research to be presented at the 32^nd Annual EAU Congress, London] Press Release

Caris Life Sciences Announces Presentations Demonstrating the Broad Capabilities of ADAPT Biotargeting System

Caris Life Sciences^® announced four abstracts that will be presented. The broad capabilities of the company’s ADAPT Biotargeting System™ include therapeutic discovery and development, fixed tissue based companion diagnostics, blood-based cancer screening and biomarker identification. [Press release from Caris Life Sciences discussing research to be presented at the the American Association for Cancer Research (AACR) 2017 Annual Meeting, Washington, D.C.] Press Release

WntResearch Announces Positive Results from Clinical Study with Drug Candidate Foxy-5

WntResearch announces that the company has obtained positive results from the analyses of patient tumor tissue samples before and after treatment in a Phase Ib study with Foxy-5 – a drug candidate intended to inhibit tumors from spreading in cancer patients. Based on the obtained results, the company has defined the dose level for the upcoming Phase II study, which was one of the objectives with this clinical study. [WntResearch] Press Release

Blue Earth Diagnostics Receives Positive CHMP Opinion for Axumin™ (Fluciclovine (¹⁸F)) for PET Imaging of Recurrent Prostate Cancer

Blue Earth Diagnostics announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency has adopted a positive opinion recommending that Axumin™ should be granted marketing authorization in the European Union. The recommendation is for Axumin use in Positron Emission Tomography (PET) imaging to detect recurrence of prostate cancer in adult men with a suspected recurrence based on elevated blood prostate specific antigen levels after primary curative treatment. [Blue Earth Diagnostics] Press Release

Gates Foundation Announces Open-Access Publishing Venture

The Bill & Melinda Gates Foundation is set to launch its own open-access publishing venture later this year. The initiative, Gates Open Research, will be modeled on a service begun last year by the London-based biomedical charity, the Wellcome Trust. Like that effort, the Gates Foundation’s platform is intended to accelerate the publication of articles and data from research funded by the charity. [Nature News] Editorial

Canada Budget Falls Flat With Scientists

The budget that Canadian Prime Minister Justin Trudeau’s government released lives up to his promises to emphasize innovation, and to encourage links between industry and academia. But it also presents scientists with a depressing, and unexpected, freeze on the main funding streams for basic research. [Nature News] Editorial

South Korea’s Scientists Seek Change amid Political Chaos

When South Korea’s Constitutional Court removed scandal-ridden President Park Geun-hye from office on 10^th March, citizens rejoiced in the streets — and many scientists breathed a sigh of relief. Her downfall has inspired a public appetite for broad governmental reforms, including changes in how the country supports scientific research. Many in the research community hope to end South Korea’s decades-long focus on applied research and shift more resources to basic science. [Nature News] Editorial

NEW Regulation and Function of Small GTPases
June 11-16, 2017
West Palm Beach, United States

Visit our events page to see a complete list of events in the community.

NEW Postdoctoral Fellow – Prostate Cancer (Johns Hopkins University)

NEW Postdoctoral Fellow – Prostate/Pancreatic Cancer (Medical College of Wisconsin)

Postdoctoral Fellow – Prostate Cancer Research (Vancouver Prostate Center)

PhD Student – Prostate Cancer Research (Vancouver Prostate Center)

Faculty Position – Urologic Pathology (University of California Los Angeles)

Postdoctoral Fellow – Computational Cancer Biology (European Molecular Biology Laboratory)

Postdoctoral Research Fellow – Urological Cancers (Institute of Cancer Research)

Postdoctoral Position – Genomics and Molecular Biology (The George Washington University)

PhD Studentships – Translational Research Network for Prostate Cancer (University of Glasgow)

Assistant Professor – Molecular Therapeutics of Cancer (Dartmouth College / Geisel School of Medicine)

Recruit Top Talent: Reach potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.

Have we missed an important article or publication in Prostate Cell News? Click here to submit!

Comments or suggestions? Submit your feedback here.